Navigation Links
Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
Date:11/10/2008

ith@pharmasset.com

Office: +1 (609) 613-4181

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section of our Annual Report on Form 10-K for the fiscal year ended September 30, 2007 filed with the Securities and Exchange Commission entitled "Risk Factors" and discussions of potential risks and uncertainties in our subsequent filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
2. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
3. InterMune Announces Progress on Pirfenidone in IPF
4. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
5. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
6. InterMune Announces Start of Phase 1b Trial of ITMN-191
7. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
8. Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
9. Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th
10. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
11. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015 Perrigo Company ... on the Mylan N.V. ("Mylan") (NASDAQ: MYL ) ... Perrigo. "Our views of Mylan,s offer to ... be, based on our Board,s careful reflection of the ... on the limited choices that Mylan has allowed its ...
(Date:8/28/2015)... August 28, 2015 The report "Eubiotics Market by ... Poultry, Ruminant, and Aquaculture), & by Region ( North ... Asia-Pacific , and Rest of the World) - Global ... market for Eubiotics was valued at USD 4.62 Billion in ... 2020, at a CAGR of 7.4% from 2015 to 2020. ...
(Date:8/27/2015)...  A recent study by Feucht et al, ... Arthrosurface HemiCAP® Wave implant, which is based on ... implant for isolated patellofemoral disease. While both implant ... scores, none of the patients in the "inlay" ... of the patients in the "onlay" group, showed ...
Breaking Medicine Technology:Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3
... May 12, 2011 Polaris Group (Polaris) today announced ... its Phase 3-ready pegylated arginine deiminase, ADI-PEG 20, during ... p.m. China Standard Time in Taipei, Taiwan. ... of ADI-PEG 20 in hepatocellular carcinoma (HCC) will be ...
... SANTA CLARA, Calif., May 12, 2011 Cell Biosciences, ... Inc. of Ottawa, Ontario for approximately U.S. $9 million ... market leader in Micro-Flow Imaging (MFI), an analytical technique ... Because of high interest in protein aggregation expressed by ...
Cached Medicine Technology:Polaris Group to Highlight Clinical Development Plans for Phase 3-Ready Candidate, ADI-PEG 20, During Symposium in Taiwan 2Polaris Group to Highlight Clinical Development Plans for Phase 3-Ready Candidate, ADI-PEG 20, During Symposium in Taiwan 3Cell Biosciences Acquires Brightwell Technologies 2
(Date:8/30/2015)... ... ... Natural Rest contains a unique mixture of vitamins and herbs that are ... to improve mood disorders and anxiety. Like all other Creative Medical Health products, Natural ... regenerative medicine conducted by Dr. Amit Patel of the University of Utah, one of ...
(Date:8/30/2015)... ... 30, 2015 , ... SonaCare Medical, LLC, the makers of ... cancer, has announced the roll-out of its newest technology – called Sonafuse ... Mexico. , The Sonablate® technology currently in use at the San Javier Marina ...
(Date:8/29/2015)... ... August 29, 2015 , ... On Saturday, September 19, 2015, ... Research Foundation (Meso Foundation) will present an educational program titled “Asbestos and Your ... lasts through 9:30 PM (doors open at 6:45pm) at Calvary United Methodist Church, 16 ...
(Date:8/29/2015)... ... ... Dr. Tim Novelli, DC., Founder and President of the Patriot Project, is ... chiropractic field in the military. All too often VA hospitals treat patients with harmful ... to the VA program over a decade ago, the reality is that only 10% ...
(Date:8/29/2015)... AB (PRWEB) , ... August 29, 2015 , ... ... heart failure, angina, chronic obstructive pulmonary disease (including emphysema), or asthma, are at ... such as angina, previous heart attack, heart failure or heart-rhythm problems (arrhythmia or ...
Breaking Medicine News(10 mins):Health News:Creative Medical Health’s Natural Rest® Now Available on ReCreative Medical Health’s Natural Rest® Now Available on RevNutrition.com 2Health News:Image Fusion Technology Combines MRI and Ultrasound Images to Treat Prostate Cancer 2Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2
... first U.S. clinical trial using genetic screening to ... therapies supports the use of those drugs as ... failed. While the study led by Massachusetts General ... (Iressa) treatment considerably improved the outcomes for non-small-cell-lung-cancer ...
... at the University of Illinois report this week that a ... can disrupt a key component of the inflammatory response in ... and diseases such as Alzheimers and multiple sclerosis. , ... Academy of Sciences. , Inflammation can be a blessing or ...
... the ... chance to change people,s lives, OTTAWA, May 20 ... for new ways to make the most of their,time, especially ... independent marketing opportunities provided by,Melaleuca, The Wellness Company(R)., One ...
... Anthem,s Care Comparison Tool Gives Members the Most Complete Picture ... Costs Associated with Medical ... Cross and,Blue Shield (Anthem) announced today the expansion of its ... access,to Anthem Care Comparison, an online tool that provides total ...
... WASHINGTON, May 20 Wednesday, May 21, 2008,Easter Seals ... Senator Mary Landrieu and Capital One for,their efforts on ... Advocacy Awards Benefit will be held at the JW ... pm and dinner at 7:00,pm. Gordon Peterson of WJLA ...
... May 20 Despite the clear benefits of,lipid-modifying ... in a new supplement to The Journal of ... aggressive,lipid lowering" reviews the evidence from recent trials ... and the use of,statins to improve outcomes in ...
Cached Medicine News:Health News:Determining genetic signature of lung tumors can help guide treatment 2Health News:Determining genetic signature of lung tumors can help guide treatment 3Health News:Plant flavonoid found to reduce inflammatory response in the brain 2Health News:Plant flavonoid found to reduce inflammatory response in the brain 3Health News:Lucrative Sales Opportunities Abound With Melaleuca, The Wellness Company(R) 2Health News:Anthem Blue Cross and Blue Shield Introduces Transparency Initiative in Maine 2Health News:Anthem Blue Cross and Blue Shield Introduces Transparency Initiative in Maine 3Health News:Reductions in CV Morbidity and Mortality are Achievable! 2
Wellpro 96 an automated liquid handling system for 96-well plates that quickly and accurately prepares large quantities of serial dilutions. The Wellpro also performs plate to plate transfers using ...
... Recovery with The aliquot! The aliquot from ... dispenser compatible with 96, 384, and 1536 ... dispensing action, backfilling facility and optional microplate ... to your low volume dispensing needs. The ...
... 384 is a compact and self-contained ... is a unique flow-through device, which ... included wash system. Optional refill ... system. Will be upgradable to ...
... The Aquarius 96 is a compact and ... optional fixed tip manifold can be used ... efficiently washed in the optional active wash ... to dust and adds safety. ...
Medicine Products: